The CREST biorepository: A tool for molecular epidemiology and translational studies on malignant mesothelioma, lung cancer, and other respiratory tract diseases

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 11, 2008, Pages 3013-3019

  Donatella, Ugolini ^a,b,c   Monica, Neri ^b   Aldo, Canessa Pier ^e   Cristina, Casilli ^a,b   Giuseppe, Catrambone ^c   Paolo, Ivaldi Giovanni ^d   Cecilia, Lando ^b   Paola, Marroni ^b   Michela, Paganuzzi ^b   Barbara, Parodi ^b   Paola, Visconti ^b   Riccardo, Puntoni ^b   Stefano, Bonassi ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b National Cancer Research Institute

^c UNIVERSITY OF GENOA   (Italy)

^d VILLA SCASSI HOSPITAL   (Italy)

^e Ospedale San Bartolomeo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPSY; BLOOD; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; HUMAN; LUNG CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MOLECULAR EPIDEMIOLOGY; PLASMA; PLEURA FLUID; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT CANCER; RESPIRATORY TRACT DISEASE; SALIVA; SERUM;

EPIDEMIOLOGY, MOLECULAR; HUMANS; INFORMED CONSENT; ITALY; MESOTHELIOMA; PLEURAL NEOPLASMS; QUESTIONNAIRES; RESPIRATORY TRACT DISEASES; TISSUE BANKS; TUMOR MARKERS, BIOLOGICAL;

EID: 55849093242     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0524     Document Type: Article

References (39)

1. Bonassi S, Neri M. Genetic biomarkers in human population studies. In: Willard HF, Ginsburg GS, editors. Handbook of genomic medicine. Elsevier. In press 2008.
2. Ambrosone CB, Nesline MK, Davis W. Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiol Biomarkers Prev 2006;15:1575-7.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
4. Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
5. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29: 14-9.
6. Gennaro V, Ugolini D, Viarengo P, et al. Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002). Eur J Cancer 2005; 41:2709-14.
7. National Cancer Institute, National Institute of Health, US Department of Health and Human Services. National Cancer Institute. Best practices for biospecimens resources. June 2007. http://biospecimens.cancer.gov/practices/.
8. ISBER (International Society for Biological and Environmental Repositories). Best practices for repositories: collection, storage, and retrieval of human biological materials for research. Cell Preserv Technol 2005;3:5-48.
9. Holland NT, Smith MT, Eskenazi B, Bastaki M. Biological sample collection and processing for molecular epidemiological studies. Mutat Res 2003;543:217-34.
10. Holland NT, Pfleger L, Berger E, Ho A, Bastaki M. Molecular epidemiology biomarkers-sample collection and processing considerations. Toxicol Appl Pharmacol 2005;206:261-8.
11. OECD Best Practice Guidelines for Biological Resource Centres, OECD 2007 http://www.oecd.org/document/36/0,3343,en_2649_ 37407_38777060_1_1_1_37407,00. html.
12. Common minimum technical standards and protocols for biological resource centres dedicated to cancer research, Workgroup Report 2. Caboux E, Plymoth A, Hainaut P, editors. IARC; 2007.
13. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985;147:29-36.
14. Sambrook J, Fritsch E., Maniatis T. Molecular cloning, a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
15. Cormier TA, Tran K, Forman JE, Jackson A, Lem P, Hardenbol P. SNP genotyping of saliva DNA using Affimetrix GeneChip targeted genotyping system http://www.dnagenotek.com/pdf_files/ Affymetrix_SNP_Genotyping.pdf.
16. Rylander-Rudqvist T, Håkansson N, Tybring G, Wolk A. Quality and quantity of saliva DNA obtained from the self-administrated Oragene method - a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomarkers Prev 2006;15:1742-5.
17. Magistrelli P, Neri M, Granone P, Cesario A, Russo P. K-Ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value. Pancreas 2008;37:101-2.
18. Landi S, Gemignani F, Bottari F, et al. MnSOD and GST's polymorphisms affects the risk of malignant pleural mesothelioma. Int J Cancer 2007;120:2739-43.
19. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81.
20. Neri M, Taioli E, Filiberti R. Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian study populations. Int J Hyg Environ Health 2006;209:393-8.
21. Neri M, Cesario A, Granone P, et al. Prognostic role of K-ras mutations in non-small-cell lung cancer: still an issue for open debate. Lung Cancer 2006;53:393-5.
22. Neri M, Filiberti R, Taioli E, et al. Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat Res 2005;592: 36-44.
23. Bolognesi C, Martini F, Tognon M, et al. A molecular epidemiology case control study on pleural malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2005;14:1741-6.
24. Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 2005;65: 3049-52.
25. Trombino S, Neri M, Puntoni R, et al. K-Ras codon 12 mutations detected in plasma DNA is not an indicator of disease in NSCLC patients. Clin Chem 2005;51:1313-4.
26. Filiberti R, Marroni P, Neri M, et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol 2005;26:221-6.
27. Neri M, Betta PG, Marroni P, et al. Serum anti-p53 autoantibodies in lung cancer, pleural mesothelioma and non-malignant lung diseases. Lung Cancer 2003;39:165-72.
28. Bolognesi C, Filiberti R, Neri M, et al. High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma. Cancer Res 2002;62:5418-9.
29. Filiberti R, Marroni P, Paganuzzi M, et al. c-erbB-2 protein in serum of primary lung cancer patients. Cancer Detect Prev 2002;26: 64-8.
30. Rossi O, Filiberti R, Neri M, et al. Incision of AP sites in lung cancer patients: a pilot study. Teratog Carcinog Mutagen 2002;22: 251-6.
31. Ardizzoni A, Cafferata MA, Paganuzzi M, et al. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Cancer 2001;92:1896-904.
32. Neri M, Geido E, Filiberti R, et al. Analysis of erythrocyte glycophorin-A variants by flow cytometry in lung disease patients detects the effect of tobacco smoke. Anal Cell Pathol 2000;21:35-40.
33. Ugolini D, Neri M, Ceppi M, et al. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. Mutat Res 2008;658:162-17.
34. Betti M, Neri M, Ferrante D, et al. Pooled analysis of NAT2 genotypes as risk factor for asbestos-related malignant mesothelioma. Int J Hyg Environ Health 2008, in press.
35. Mohanty SK, Mistry AT, Amin W, et al. The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue Bank. BMCC ancer 2008;8:91.
36. Neri M, Ugolini D, Dianzani I, et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res 2008;659:126-36.
37. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinicacetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7.
38. Amos CI, Wu X, Broderick P. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-22.
39. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheralarterial disease. Nature 2008;452:638-42.